Ibritumomab Tiuxetan (Zevalin)

DRUG4 trials

Sponsors

M.D. Anderson Cancer Center, University Hospital, Bordeaux, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Chonnam National University Hospital

Conditions

Diffuse Large B-Cell LymphomaLymphomaLymphoma, Large B-Cell, DiffuseMantle Cell LymphomaNon-Hodgkin Lymphoma

Phase 2

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

CompletedNCT00493467

M.D. Anderson Cancer CenterLymphoma

Start: 2006-06-30End: 2022-08-11Updated: 2022-09-15

Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

CompletedNCT00607854

University Hospital, BordeauxDiffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma

Start: 2008-02-29End: 2011-11-30Updated: 2016-10-05

Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)

CompletedNCT00644371

Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNon-Hodgkin Lymphoma

Start: 2007-11-30End: 2013-02-04Updated: 2017-03-27

90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma

CompletedNCT01157988

Chonnam National University HospitalLymphoma, Large B-Cell, Diffuse

Start: 2007-01-31Updated: 2010-07-08

Related Papers

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

Biology of Blood and Marrow Transplantation2016-10-1915 citations

90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.

2014-10-305 citations